No Data
No Data
Clinuvel Pharmaceuticals Cut to Hold From Add by Morgans >CUV.AU
Clinuvel Pharmaceuticals Cut to Hold From Add by Morgans >CUV.AU
Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold From Add; Price Target Is AU$16
Clinuvel Pharmaceuticals (ASX:CUV) has an average rating of buy and price targets ranging from AU$16 to AU$48, according to analysts polled by CapitalIQ. Price (AUD): $15.51, Change: $-1.87, Percent C
Stocks of the Hour: Clinuvel Pharmaceuticals, Mt Malcolm Mines, Auric Mining
To register for today's webinar click here.Clinuvel Pharmaceuticals (ASX:CUV) announced the final set of results from a study evaluating the DNA-repair capacity of afamelanotide on skin of healthy vol
Clinuvel Price Target Raised 23% to A$31.38/Share by Wilsons
Clinuvel Price Target Raised 23% to A$31.38/Share by Wilsons
Clinuvel Pharmaceuticals Secures Orphan Drug Designation in Europe for Metabolic Disorder Drug
Clinuvel Pharmaceuticals (ASX:CUV) secured an orphan drug designation from the European Medicines Agency for the use of the Scenesse-branded afamelanotide in patients with variegate porphyria, a genet
Clinuvel Pharmaceuticals' Afamelanotide Found Effective in Fair-Skinned Parkinson's Patients
Clinuvel Pharmaceuticals' (ASX:CUV) proprietary first-in-class photoprotective drug afamelanotide was found to have a positive impact in fair-skinned patients of early-stage Parkinson's disease, accor
No Data
practical Moose_io3 : K